USANA (NYSE:USNA) Exceeds Q1 Expectations, Full-Year Sales Guidance is Optimistic Health and wellness products company USANA Health Sciences (NYSE:USNA) reported Q1 CY2025 results beating Wall Street’s revenue expectations , with sales up 9.7% year on year to $250 million. The company’s full-year revenue guidance of $960 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $0.73 per share was 4.3% above analysts’ consensus estimates. Is now the time to buy USANA? Find out in our full research report. USANA (USNA) Q1 CY2025 Highlights: Revenue: $250 million vs analyst estimates of $243 million (9.7% year-on-year growth, 2.9% beat) Adjusted EPS: $0.73 vs analyst estimates of $0.70 (4.3% beat) The company reconfirmed its revenue guidance for the full year of $960 million at the midpoint Management reiterated its full-year Adjusted EPS guidance of $2.68 at the midpoint EBITDA guidance for the full year is $115 million at the midpoint Operating Margin: 8.4%, down from 10.8% in the same quarter last year Market Capitalization: $449.4 million Company Overview Going to market with a direct selling model rather than through traditional retailers, USANA Health Sciences (NYSE:USNA) manufactures and sells nutritional, personal care, and skincare products. Personal Care While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products. Sales Growth Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. With $876.7 million in revenue over the past 12 months, USANA is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers. As you can see below, USANA struggled to generate demand over the last three years. Its sales dropped by 8.7% annually, a poor baseline for our analysis.USANA Quarterly Revenue This quarter, USANA reported year-on-year revenue growth of 9.7%, and its $250 million of revenue exceeded Wall Street’s estimates by 2.9%. Looking ahead, sell-side analysts expect revenue to grow 8.6% over the next 12 months, an acceleration versus the last three years. This projection is healthy and suggests its newer products will catalyze better top-line performance. Story Continues Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Cash Is King Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. USANA has shown decent cash profitability, giving it some flexibility to reinvest or return capital to investors. The company’s free cash flow margin averaged 6.3% over the last two years, slightly better than the broader consumer staples sector.USANA Trailing 12-Month Free Cash Flow Margin Key Takeaways from USANA’s Q1 Results It was great to see USANA’s full-year revenue guidance top analysts’ expectations. We were also happy its revenue and EPS outperformed Wall Street’s estimates. Overall, we think this was a decent quarter with some key metrics above expectations. The stock remained flat at $24.24 immediately following the results. Is USANA an attractive investment opportunity right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it’s free. View Comments
USANA (NYSE:USNA) Exceeds Q1 Expectations, Full-Year Sales Guidance is Optimistic
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...